The BALL prognostic score identifies relapsed/refractory CLL patients who benefit the most from single-agent ibrutinib therapy

Leuk Res. 2020 Aug:95:106401. doi: 10.1016/j.leukres.2020.106401. Epub 2020 Jun 10.
No abstract available

Keywords: BALL score; Ibrutinib; Overall survival; Relapsed/refractory CLL.

Publication types

  • Letter

MeSH terms

  • Adenine / analogs & derivatives
  • Adult
  • Aged
  • Aged, 80 and over
  • Antineoplastic Agents / therapeutic use*
  • Biomarkers, Tumor / blood
  • Female
  • Hemoglobins / analysis
  • Humans
  • L-Lactate Dehydrogenase / blood
  • Leukemia, Lymphocytic, Chronic, B-Cell / blood
  • Leukemia, Lymphocytic, Chronic, B-Cell / drug therapy*
  • Male
  • Middle Aged
  • Neoplasm Recurrence, Local / drug therapy*
  • Piperidines
  • Prognosis
  • Protein Kinase Inhibitors / therapeutic use
  • Pyrazoles / therapeutic use*
  • Pyrimidines / therapeutic use*
  • Time Factors
  • beta 2-Microglobulin / blood

Substances

  • Antineoplastic Agents
  • Biomarkers, Tumor
  • Hemoglobins
  • Piperidines
  • Protein Kinase Inhibitors
  • Pyrazoles
  • Pyrimidines
  • beta 2-Microglobulin
  • ibrutinib
  • L-Lactate Dehydrogenase
  • Adenine